Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Peter A, MD
16 Juni 2021 19:02:45
Cefuroxime na ujauzito
Cefuroxime ni dawa ya antibiotic katika kundi la cephalosporin, dawa hii hutumiwa kwa kunywa au kuchoma. Tafiti za panya zimeonyesha dawa haina madhara kwenye uzazi kwenye dozi iliyotumika ambayo ni sawa na mara 9 ya dozi inayotakiwa kutumika kwa binadamu, panya, na nyani.
Kiasi kidogo huingia kwenye maziwa ya mama na humpata mtoto na kuleta madhara ya kubadilisha bakteria rafiki kwenye mfumo wa tumbo la mtoto, kutoa majibu ya kuotesha bakteria yasiyo sahihi endapo mtoto ana homa na madhara ya moja kwa moja kwa mtoto. Hata hivyo wataaluma wameweka dawa hii kuwa salama kutumika kwa mama aonyonyesha.
Ushauri dhidi ya matumizi kwa mama mjamzito
Inapatana na ujauzito
Inapatana na ujauzito ina maanisha nini?
Uzoefu wa matumizi kwa binadamu kuhusu dawa hii au dawa zingine zilizo kundi moja au zenye kufanya kazi kwa utaratibu unaofanana, zinatosha kuonyesha kuwa, madhara kwa kichanga tumboni ni madogo sana au hakuna kabisa. Tafiti za uzazi kwa wanyama hazina uhalisia kwa binadamu.
Ushauri wa matumizi kwa mama anayenyonyesha
Inapatana na unyonyeshaji
Inapatana na unyonyeshaji ina maanisha nini?
Kiasi kidogo cha dawa hii kinawezekana kuingia kwenye maziwa ya mama, kiasi hiki hakina mashiko ya kusababisha sumu kwa kichanga anayenyonya. Dawa hii haitarajiwi kusababisha madhara kwa kichanga anayenyonya maziwa ya mama anayetumia dawa hii.
ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeboreshwa,
1 Julai 2023 17:20:41
Rejea za mada hii;
1. Product information. Ceftin. Glaxo Wellcome, 1997.
2. Craft I, Mullinger BM, Kennedy MRK. Placental transfer of cefuroxime. Br J Obstet Gynaecol 1981;88:141–5.
3. Bousfield P, Browning AK, Mullinger BM, Elstein M. Cefuroxime: potential use in pregnant women at term. Br J Obstet Gynaecol 1981;88:146–9.
4. Bergogne-Berezin E, Pierre J, Even P, Rouvillois JL, Dumez Y. Study of penetration of cefuroxime into bronchial secretions and of its placental transfer. Therapie 1980;35:677–84.
5. Tzingounis V, Makris N, Zolotas J, Michalas S, Aravantinos D. Cefuroxime prophylaxis in caesarean section. Pharmatherapeutica 1982;3:140–2.
6. Coppi G, Berti MA, Chehade A, Franchi I, Magro B. A study of the transplacental transfer of cefuroxime in humans. Curr Ther Res 1982;32:712–6.
7. Bousefield PF. Use of cefuroxime in pregnant women at term. Res Clin Forums 1984;6:53–8.
8. Philipson A, Stiernstedt G. Pharmacokinetics of cefuroxime in pregnancy. Am J Obstet Gynecol 1982;142:823–8.
9. Faro S, Pastorek JG II, Plauche WC, Korndorffer FA, Aldridge KE. Short-course parenteral antibiotic therapy for pyelonephritis in pregnancy. S Med J 1984;77:455–7.
10. Holt DE, Fisk NM, Spencer JAD, de Louvlis J, Hurley R, Harvey D. Transplacental transfer of cefuroxime in uncomplicated pregnancies and those complicated by hydrops or changes in amniotic fluid volume. Arch Dis Child 1993;68:54–7.
11. De Leeuw JW, Roumen FJME, Bouckaert PXJM, Cremers HMHG, Vree TB. Achievement of therapeutic concentrations of cefuroxime in early preterm gestations with premature rupture of the membranes. Obstet Gynecol 1993;81:255–60.
12. Berkovitch M, Segal-Socher I, Greenberg R, Bulkowshtein M, Arnon J, Perlob P, Or-Noy A. First trimester exposure to cefuroxime: a prospective cohort study. Br J Clin Pharmacol 2000;50:161–5.